The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A first-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers.
 
Branimir I. Sikic
Stock and Other Ownership Interests - Arena Pharma
Consulting or Advisory Role - Concert Pharmaceuticals; Gilead Sciences; Immune Design; Pfizer; Threshold Pharmaceuticals
Research Funding - Basilea (Inst); Celldex (Inst); Exelixis (Inst); Genentech (Inst); Novartis (Inst); Sanofi (Inst)
 
Sujata Narayanan
No Relationships to Disclose
 
A. Dimitrios Colevas
Stock and Other Ownership Interests - Gilead Sciences; Pharmacyclics
Research Funding - Bristol-Myers Squibb; Curis; Genentech
 
Sukhmani Kaur Padda
Consulting or Advisory Role - Clovis Oncology
 
George A. Fisher
Stock and Other Ownership Interests - Seagen (I)
Consulting or Advisory Role - Celgene; ipsen
Research Funding - Bristol-Myers Squibb (Inst); EpicentRx (Inst); Genentech/Roche (Inst); Newlink Genetics (Inst); Pharmaceutical Research Associates (Inst); Polaris (Inst); Tercica (Inst); XBiotech (Inst)
Travel, Accommodations, Expenses - Genentech/Roche
 
Dana Supan
No Relationships to Disclose
 
Heather A. Wakelee
Honoraria - ACEA Biosciences; Biocon; Helsinn Therapeutics; Peregrine Pharmaceuticals; Pfizer
Consulting or Advisory Role - ACEA Biosciences; Helsinn Therapeutics; Peregrine Pharmaceuticals; Pfizer
Research Funding - Agennix (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Exelixis (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Xcovery (Inst)
Travel, Accommodations, Expenses - ACEA Biosciences; Clovis Oncology; Novartis; Pfizer
 
Rhonda Aoki
No Relationships to Disclose
 
Mark D. Pegram
Employment - Dava Oncology (I)
Consulting or Advisory Role - Genenetech, Pfizer, Novartis, AstraZeneca
Expert Testimony - Novartis
Travel, Accommodations, Expenses - Genentech, Pfizer, Novartis
Other Relationship - Genentech, Pfizer, Novartis, AstraZeneca
 
Victor Manuel Villalobos
Consulting or Advisory Role - Janssen
Travel, Accommodations, Expenses - Lilly
 
Jie Liu
Stock and Other Ownership Interests - Forty Seven
Consulting or Advisory Role - Forty Seven
Patents, Royalties, Other Intellectual Property - Forty Seven
 
Mark Chao
Employment - Forty Seven
Stock and Other Ownership Interests - Forty Seven
Consulting or Advisory Role - Forty Seven
Patents, Royalties, Other Intellectual Property - Forty Seven
 
Jens-Peter Volkmer
Stock and Other Ownership Interests - Forty Seven
Consulting or Advisory Role - Forty Seven
Patents, Royalties, Other Intellectual Property - Forty Seven
 
Ravindra Majeti
Employment - BioDuro (I); PPD (I)
Leadership - Forty Seven
Stock and Other Ownership Interests - Amgen (I); Forty Seven
Honoraria - Agios
Consulting or Advisory Role - Forty Seven
Patents, Royalties, Other Intellectual Property - Forty Seven
 
Irving L Weissman
Employment - Stem Cells, Inc. (I)
Leadership - Forty Seven; Stem Cells, Inc.
Stock and Other Ownership Interests - Forty Seven; Stem Cells, Inc.
Consulting or Advisory Role - Forty Seven; Stem Cells, Inc.
Patents, Royalties, Other Intellectual Property - Forty Seven; Stem Cells, Inc.